SAN DIEGO, June 27, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq:APRI) announced today that, based on a successful and statistically significant reanalysis of its U.S. Phase III trials for its MycoVa™ product, originally intended for treating onychomycosis (nail fungus), it is revisiting its regulatory strategy for the drug. Specifically, a combined post-hoc analysis of two randomized, double-blind, vehicle controlled, multicenter, parallel group Phase III studies to assess the efficacy, safety and tolerability of MycoVa™, demonstrated statistically significant results in mycological cure, resulting in the eradication of nail fungus in favor of active treatment in patients who did not present with comorbid tinea pedis (athlete’s foot), as these patients are considered at higher risk of reinfection.
